Pioglitazone-d4 (alkyl)

• 常用名: Pioglitazone-d4 (alkyl)
• 英文名: Pioglitazone-d4 (alkyl)
• CAS号: 1134163-31-7
• 分子量: 360.46300
• 密度: N/A
• 沸点: N/A
• 分子式: C₁₉H₁₆D₄N₂O₃S
• 熔点: N/A
• 闪点: N/A

Pioglitazone-d4 (alkyl)用途

吡格列酮-d4(烷基)(U 72107-d4(烷基))是氘标记的吡格列酮。吡格列酮(U 72107)是一种有效的选择性PPARγ激动剂,与人和小鼠PPARγ配体结合域具有高亲和力结合,EC50分别为0.93和0.99μM[1][2]。

Pioglitazone-d4 (alkyl)名称

• 中文名: 吡格列酮-d4
• 英文名: 5-[[4-[1,1,2,2-tetradeuterio-2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Pioglitazone-d4 (alkyl)生物活性

• 描述: 吡格列酮-d4(烷基)(U 72107-d4(烷基))是氘标记的吡格列酮。吡格列酮(U 72107)是一种有效的选择性PPARγ激动剂,与人和小鼠PPARγ配体结合域具有高亲和力结合,EC50分别为0.93和0.99μM[1][2]。
• 相关类别:
  研究领域 >> 癌症
  信号通路 >> 细胞凋亡 >> Ferroptosis
  信号通路 >> 细胞周期/DNA损伤 >> PPAR
  研究领域 >> 代谢疾病
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
• 参考文献:

  [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve

  [3]. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.

  [4]. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.

  [5]. Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33.

Pioglitazone-d4 (alkyl)物理化学性质

• 分子式: C₁₉H₁₆D₄N₂O₃S
• 分子量: 360.46300
• 精确质量: 360.14500
• PSA: 97.08000
• LogP: 3.43550

Pioglitazone-d4 (alkyl)英文别名

• Pioglitazone-Labeled d4
• Pioglitazone-d4
• AD-4833-d4
• Actos-d4